Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy | Zendy

Alison U. Barron | Zendy; Tanya L. Hoskin | Zendy; Courtney N. Day | Zendy; E. Shelley Hwang | Zendy; Henry M. Kuerer | Zendy; Judy C. Boughey | Zendy

Open Access

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

Author(s) -

Alison U. Barron,

Tanya L. Hoskin,

Courtney N. Day,

E. Shelley Hwang,

Henry M. Kuerer,

Judy C. Boughey

Publication year - 2018

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2018.2696

Subject(s) - medicine , breast cancer , triple negative breast cancer , oncology , chemotherapy , neoadjuvant therapy , complete response , triple negative , cancer

A recent publication reported that of 527 patients with clinically node-negative (cN0) cT1/cT2 triple-negative breast cancer (TNBC) or ERBB2-positive disease treated with neoadjuvant chemotherapy (NAC), 100% of those who achieved a breast pathologic complete response (pCR) had pathologic node negativity (pN0). Eliminating axillary surgery in these patients has been suggested as safe based on these results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research